Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed chronic phase chronic myelogenous leukemia (CML)~  * bcr-abl positive~ * No blasts, promyelocytes, myelocytes, or metamyelocytes in the peripheral blood~* Availability of a HLA-identical sibling or unrelated donor~PATIENT CHARACTERISTICS:~Age~* Any age~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No second malignancy requiring therapy~* No evidence of disease-related symptoms or extramedullary disease (including hepatosplenomegaly)~* No serious diseases that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior interferon~Chemotherapy~* No prior chemotherapy other than hydroxyurea~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy~Surgery~* Not specified~Other~* Prior anagrelide allowed~* No participation in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).